TY - JOUR AU - Chen, Zhijun AU - Song, Zihan AU - Den, Shichen AU - Zhang, Wei AU - Han, Mengjia AU - Lan, Tianhang AU - Du, Xiaokang AU - Ning, Jingyun AU - Chen, Xinhui AU - Lin, Haoming AU - Zhang, Rui TI - Application of Immune Checkpoint Inhibitors in Cancer JF - MEDCOMM J2 - MEDCOMM VL - 6 PY - 2025 IS - 8 PG - 43 SN - 2688-2663 DO - 10.1002/mco2.70176 UR - https://m2.mtmt.hu/api/publication/36364226 ID - 36364226 LA - English DB - MTMT ER - TY - JOUR AU - Duan, Qingyuan AU - Zhang, Xueying AU - Li, Minjie TI - Rhabdomyolysis as a Predominant Multisystem Serious Immune-Related Adverse Event Induced by Sintilimab: A Case Report and Literature Review JF - CANCER MANAGEMENT AND RESEARCH J2 - CANCER MANAG RES VL - 17 PY - 2025 SP - 3383 EP - 3392 PG - 10 SN - 1179-1322 DO - 10.2147/CMAR.S564116 UR - https://m2.mtmt.hu/api/publication/37020309 ID - 37020309 LA - English DB - MTMT ER - TY - JOUR AU - Gergely, Tamás G AU - Drobni, Zsófia AU - Sayour, Viktor Nabil AU - Ferdinandy, Péter AU - Varga, Zoltán TI - Molecular fingerprints of cardiovascular toxicities of immune checkpoint inhibitors JF - BASIC RESEARCH IN CARDIOLOGY J2 - BASIC RES CARDIOL VL - 120 PY - 2025 IS - 1 SP - 187 EP - 205 PG - 19 SN - 0300-8428 DO - 10.1007/s00395-024-01068-8 UR - https://m2.mtmt.hu/api/publication/35140697 ID - 35140697 N1 - Export Date: 09 April 2025; Cited By: 5; CODEN: BRCAB AB - Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy by unleashing the power of the immune system against malignant cells. However, their use is associated with a spectrum of adverse effects, including cardiovascular complications, which can pose significant clinical challenges. Several mechanisms contribute to cardiovascular toxicity associated with ICIs. First, the dysregulation of immune checkpoints, such as cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed cell death protein-1 (PD-1) and its ligand (PD-L1), and molecular mimicry with cardiac autoantigens, leads to immune-related adverse events, including myocarditis and vasculitis. These events result from the aberrant activation of T cells against self-antigens within the myocardium or vascular endothelium. Second, the disruption of immune homeostasis by ICIs can lead to autoimmune-mediated inflammation of cardiac tissues, manifesting as cardiac dysfunction and heart failure, arrhythmias, or pericarditis. Furthermore, the upregulation of inflammatory cytokines, particularly tumor necrosis factor-alpha, interferon-γ, interleukin-1β, interleukin-6, and interleukin-17 contributes to cardiac and endothelial dysfunction, plaque destabilization, and thrombosis, exacerbating cardiovascular risk on the long term. Understanding the intricate mechanisms of cardiovascular side effects induced by ICIs is crucial for optimizing patient care and to ensure the safe and effective integration of immunotherapy into a broader range of cancer treatment protocols. The clinical implications of these mechanisms underscore the importance of vigilant monitoring and early detection of cardiovascular toxicity in patients receiving ICIs. Future use of these key pathological mediators as biomarkers may aid in prompt diagnosis of cardiotoxicity and will allow timely interventions. LA - English DB - MTMT ER - TY - JOUR AU - Hsu, Chia-Lu AU - Hsu, Li-Fan AU - To, Sheng-Yin AU - Lee, Cho-Hao AU - Wen, Yuan-Liang AU - Yang, Hui-Wen AU - Chen, I-Wen AU - Kao, Li-Ting TI - Healthcare utilization in cancer patients treated with immune checkpoint inhibitors: a population-based study of all patients and 1-year survivors JF - SUPPORTIVE CARE IN CANCER J2 - SUPPORT CARE CANCER VL - 33 PY - 2025 IS - 12 PG - 11 SN - 0941-4355 DO - 10.1007/s00520-025-10127-2 UR - https://m2.mtmt.hu/api/publication/36464395 ID - 36464395 LA - English DB - MTMT ER - TY - JOUR AU - Liu, J. AU - Wang, Y. AU - Song, Z. AU - Zhang, Y. TI - Nanoengineered immune check point inhibitors delivery for targeted brain cancer treatment: Current status and future perspectives JF - BIOCHEMICAL PHARMACOLOGY J2 - BIOCHEMIC PHARMACOL VL - 233 PY - 2025 PG - 15 SN - 0006-2952 DO - 10.1016/j.bcp.2025.116789 UR - https://m2.mtmt.hu/api/publication/35780405 ID - 35780405 AB - Brain tumors create special difficulties because of their position and the protective covering of blood brain barrier (BBB) that restricts efficient medication access. Treatment alternatives such as surgery and chemotherapy demonstrate poor performance against severe brain tumors. The use of immune checkpoint inhibitors (ICIs) hints at effective cancer therapy; however, their application to brain cancer faces challenges due to inefficient delivery through the BBB and the tumor's suppressive environment. Nanoengineering can increase the transport of ICIs to brain tumors. Numerous nano-delivery systems such as liposomes and micelles have explored ways to avoid the BBB via transcytosis and the EPR mechanism. Functionalization of nanocarriers enhances targeting tumor cells and improves treatment accuracy. New developments involve delivering ICIs together with adjuvants to change the TME and focusing on immune cells such as TAMs and Tregs to boost immunity against tumors. Nanoengineered ICIs have shown effective improvement in animal models by reducing toxicity and enhancing efficacy. Converting these successes into real clinical trials is not easy as they face regulatory concerns and safety challenges. Clinical trials currently examine the use of nanocarriers for treating brain cancer; however, scalability’ and ’long-term safety’ continue to pose challenges. Future approaches will focus on combining customized medicine with advanced nanotechnology and AI to refine treatment methods. Despite obstacles ahead, nanotechnology-based ICIs offer a hopeful approach to enhance brain cancer efficacy and address existing therapeutic constraints. © 2025 Elsevier Inc. LA - English DB - MTMT ER - TY - JOUR AU - Stefanska, Barbara AU - Rabbani, Shafaat A. TI - Immunotherapy in cancer: novel approaches and future perspectives JF - BRITISH JOURNAL OF PHARMACOLOGY J2 - BR J PHARMACOL PY - 2025 PG - 8 SN - 0007-1188 DO - 10.1111/bph.70296 UR - https://m2.mtmt.hu/api/publication/36814355 ID - 36814355 LA - English DB - MTMT ER - TY - JOUR AU - Ting, Tsai Ling AU - Lee, Yuan-Ti TI - Optimizing management of immune checkpoint inhibitor-induced pancreatic enzyme elevation: Risk-based strategies JF - JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY J2 - J EUR ACAD DERMATOL PY - 2025 PG - 2 SN - 0926-9959 DO - 10.1111/jdv.70284 UR - https://m2.mtmt.hu/api/publication/36814357 ID - 36814357 LA - English DB - MTMT ER - TY - JOUR AU - Zhang, Chenxing AU - Liu, Jiaxin AU - Gu, Tiejun AU - Meng, Xiangyu AU - Cai, Xiaoyi AU - Zhang, Jinfeng AU - Chen, Yan AU - Zhang, Daguang AU - Wu, Yongge TI - Enhanced antitumor efficacy of bispecific antibody blocking PD-L1 and LAG-3 with doxorubicin: mechanism and safety evaluation JF - BREAST CANCER RESEARCH AND TREATMENT J2 - BREAST CANCER RES TR VL - 211 PY - 2025 IS - 3 SP - 637 EP - 648 PG - 12 SN - 0167-6806 DO - 10.1007/s10549-025-07676-9 UR - https://m2.mtmt.hu/api/publication/35925008 ID - 35925008 LA - English DB - MTMT ER -